Stock INFU INFUSYSTEM HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings InfuSystem Holdings, Inc.

Equities

INFU

US45685K1025

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
7.62 USD -6.16% Intraday chart for InfuSystem Holdings, Inc. -1.55% -27.70%
Apr. 10 Gregg Lehman Not to Stand for Re-Election as Director of InfuSystem Holdings, Inc CI
Mar. 14 Transcript : InfuSystem Holdings, Inc., Q4 2023 Earnings Call, Mar 14, 2024

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company does not generate enough profits, which is an alarming weak point.
  • With an expected P/E ratio at 49.16 and 18.14 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company is highly valued given the cash flows generated by its activity.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
INFUSYSTEM HOLDINGS, INC. Stock InfuSystem Holdings, Inc.
-27.70% 162M
C-
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.54% 186B
C+
MEDTRONIC PLC Stock Medtronic plc
-1.85% 107B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.26% 67.44B
A
DEXCOM, INC. Stock DexCom, Inc.
+1.39% 50.03B
B-
CENCORA, INC. Stock Cencora, Inc.
+16.82% 47.81B
B-
HOYA CORPORATION Stock Hoya Corporation
+4.79% 41.03B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+3.49% 26.85B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+0.65% 25.82B
A-
TERUMO CORPORATION Stock Terumo Corporation
+16.55% 24.74B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. INFU Stock
  4. Ratings InfuSystem Holdings, Inc.